Lv3
230 积分 2024-07-09 加入
Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma
1个月前
已完结
[Effect of TBL1XR1 Mutation on Cell Biological Characteristics of Diffuse Large B-Cell Lymphoma]
2个月前
已关闭
[Effect of TBL1XR1 Mutation on Cell Biological Characteristics of Diffuse Large B-Cell Lymphoma]
2个月前
已关闭
Mechanisms and interventions in relapsed/refractory extranodal natural killer/T-cell lymphoma
2个月前
已完结
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial
2个月前
已完结
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2个月前
已完结
Diffuse Large B-Cell Lymphoma
2个月前
已完结
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial
7个月前
已完结
Medication Use to Reduce Risk of Breast Cancer
7个月前
已关闭
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial
7个月前
已完结
皖公网安备34019202002308
